Michael Menefee, MD
Medical Oncology · Cleveland, OHNPI 1760598601
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,728 of the $4,158 with a category attached, or 89.6%. 7 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 45.5% of the total. 2025 is the largest year on record at $2,086, more than ten times the $182 reported in 2022.
Across 8 payments — averaging $519.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- G1 Therapeutics, Inc.$182
- AstraZeneca$134
- Caris MPI, Inc.$58
- Novartis$31
- plus $25 from 1 others
Across 33 payments — averaging $9352.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$238K
- GSK$39K
- Biontech SE$30K
- Boehringer Ingelheim Pharma GmbH & Co.kg$2K
- Merck$106
What the payments were for
- Consulting fees$3,72890%
- Food & beverage$43010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 1 | $1,890 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,838 |
| G1 Therapeutics, Inc. | 1 | $182 |
| AstraZeneca | 1 | $134 |
| Caris MPI, Inc. | 2 | $58 |
| Novartis | 1 | $31 |
| Eisai Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,158 in reported general payments places this provider in the 55th percentile of 157 medical oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 40 | $2,846 |
| Prochlorperazine Maleate | 50 | $667 |
| Olanzapine | 32 | $93 |
| Oxycodone Hcl | 12 | $93 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Cleveland
- Moshe OrnsteinCleveland$249K
- Suneel KamathCleveland$120K
- William TseCleveland$56K
- Amanda NizamCleveland$46K
- Melinda HsuCleveland$41K
- Jack KhouriCleveland$39K
- Jessica GeigerCleveland$33K
- Thach-Giao TruongCleveland$31K
- David PeereboomCleveland$23K
- George BuddCleveland$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.